Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple infusions of human liver cell suspension into the portal vein in children with urea cycle disorders
2006-000136-27Phase 2Completed
- Sponsor
- Cytonet
- Start
- Sep 2007
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human heterologous liver cells in urea cycle disorder (UCD) and ornithine transcarbamylase deficiency, sponsored by Cytonet. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started Sep 2007; status: completed.
02
Drugs
human heterologous liver cells
03
Conditions
urea cycle disorder (UCD)ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on 2006-000136-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000136-27.